抗汉坦病毒药物研究进展  

Research progress of anti-hantavirus drugs

作　　者：张欠欠[1] 张凯玄 郑煦暘 连建奇 ZHANG Qian-qian;ZHANG Kai-xuan;ZHENG Xu-yang;LIAN Jian-qi(Medical College of Yan'an University,Yan’an 716000,China;Department of Infectious Diseases,the Second Affiliated Hospital of Air Force Medical University)

机构地区：[1]延安大学医学院,陕西延安716000 [2]空军军医大学第二附属医院传染科

出　　处：《中国病原生物学杂志》2023年第4期482-485,共4页Journal of Pathogen Biology

基　　金：陕西省科技厅重点研发计划项目(No.2021SF-230);榆林市科技局项目(No.CXY-2020-064)。

摘　　要：汉坦病毒(Hantavirus,HTNV)作为病毒性出血热的重要病原体,是全球公共卫生的重要威胁。欧亚大陆的肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)和美洲的汉坦病毒心肺综合征(hantavirus cardiopulmonary syndrome,HCPS)是由HTNV所导致的两种严重疾病,且目前尚无特异性抗汉坦病毒药物。虽然直接抗病毒药物的研发近年取得长足进步,索磷布韦、维帕他韦等药物已经进入临床并取得显著疗效,但HTNV领域相关研究仍然较为有限。本文结合抗病毒药物研究进展,对现有抗HTNV药物,在研抗HTNV药物和抗HTNV药物的潜在靶点等方面的研究进展进行综述。Hantavirus is a serious threat to global public health,as an important pathogen of viral hemorrhagic fever,The hemorrhagic fever with renal syndrome(HFRS)in Eurasia and the Hantavirus cardiopulmonary syndrome(HCPS)are two serious diseases caused by the hantavirus,and no antiviral drugs specific for hantavirus have been used in clinical practice.Although considerable progress has been made in the research and development of direct antiviral drugs such as Sofosbuvir and Velpatasvir in recent years with remarkable efficacy,relevant studies in the field of Hantavirus are still limited.In this paper,we reviewed the existing antiviral drugs,drug development and potential drug targets for Hantavirus.

关 键 词：汉坦病毒 治疗药物 药物靶点 综述 

分 类 号：R373[医药卫生—病原生物学]